Popular search terms:

Search Results Label

57 results found

Seqirus | Influenza Pandemic Response Solutions

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com/expertise/influenza/pandemic-response-solutions
Seqirus | Influenza Expertise

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise
Seqirus | Global Manufacturing Network

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com/manufacturing/global-manufacturing-network
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-applauds-the-executive-order-to-accelerate-enhanced-protection-against-influenza-threats
Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Market

https://www.seqirus.com/news/seqirus-begins-shipping-influenza-vaccines-to-us-market
Seqirus Presents New Clinical Data Reinforcing MF59

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.com/news/seqirus-presents-new-clinical-data-reinforcing-mf59
Seqirus | Annual Disclosures

Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.seqirus.com/our-company/corporate-responsibility/disclosures
Seqirus announces major advances in pandemic preparedness

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase in seasonal influenza vaccine output in just two years, strengthening the United States’ capacity to respond to pandemic threats.

https://www.seqirus.com/news/seqirus-announces-major-advances-in-pandemic-preparedness
Fluad Tetra CHMP

Positive EMA CHMP Positive Opinion for Fluad Tetra

https://www.seqirus.com/news/fluad-tetra-chmp
Seqirus Releases First Shipment for 2019 2020 Season

Seqirus is first to begin shipping its portfolio of seasonal influenza vaccines for the upcoming 2019/20 U.S. influenza season.

https://www.seqirus.com/news/seqirus-releases-first-shipment-for-2019-2020-season